You searched for "OHT"
Risk calculation variability over time in OHT
1 June 2014
| Lorraine North
|
EYE - Glaucoma
In this study the authors aimed to assess the variability of the well documented risk model from the Ocular Hypertension Treatment Study (OHTS) that identified higher intraocular pressure (IOP), older age, lower central corneal thickness (CCT), greater vertical cup-to-disc ratio...
Intraocular pressure changes following TOHM washout
1 December 2021
| Jonathan Chan
|
EYE - Glaucoma
|
IOP phasing, prospective clinical trials, uveitic glaucoma
This retrospective study between 2008 and 2019 of 110 eyes with primary open angle glaucoma (POAG), 33 eyes with ocular hypertension (OHT) and 43 eyes with uveitic glaucoma (UG) evaluated the changes in intraocular pressure (IOP) following topical ocular hypotensive...
Ocular hypertension following intravitreal steroid injections: a comparative study between triamcinolone-acetonide and dexamethasone-implant
This was a retrospective observational study of steroid response following 1549 intravitreal steroid (TA and Dex) injections. One thousand and seventy-five eyes of 897 patients were reviewed. Glaucoma patients, glaucoma suspects, uveitis, trauma, and cases with less than one month...
Brimonidine day and night time IOP
1 October 2014
| Lorraine North
|
EYE - Glaucoma
The authors describe a randomised double masked study of 29 participants with ocular hypertension (OHT) who either self-administered 0.2% brimonidine or placebo three times daily for six weeks. Patients were seen during day time and night time visits and had...
Efficacy and safety of novel PF brimonidine / timolol fixed-combination ophthalmic solution for OAG
4 August 2021
| Su Young
|
EYE - Glaucoma
|
Open-angle glaucoma, brimonidine/timolol fixed combination, intraocular pressure, normal-tension glaucoma, preservative-free
This study is a multicentre, randomised, open-label, parallel-group clinical trial to evaluate the efficacy and safety of a newly developed preservative-free (PF) brimonidine / timolol fixed-combination (BTFC) ophthalmic solutions as compared with preservative-containing (PC) BTFC ophthalmic solution in adult patients...
Steroid treatment for pseudophakic cystoid macular oedema
1 October 2021
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Cystoid macular edema, intravitreal steroids, triamcinolone
The authors present a retrospective comparison of 45 eyes of 41 patients treated with 2mg intravitreal triamcinolone (IVT group) and 50 eyes of 42 patients treated with 40mg sub-Tenons triamcinolone (STT group) for pseudophakic cystoid macular oedema (CMO). The visual...
Real-world experience and outcomes of SLT laser used as a first-line treatment in ocular hypertension patients in a United Kingdom National Health Service setting
3 October 2022
| Aiman Jamal, Shreya Haldar, Sarah Twallin, Asifa Shaikh
The management of raised intraocular pressure (IOP) in the context of ocular hypertension (OHT) and primary open angle glaucoma (POAG) remains a major contributor to the workload of ophthalmology units across the UK. Treatment of these conditions has historically centred...
Does vitrectomy increase the risk of glaucoma? A retrospective review from a UK hospital
5 April 2022
| Aiman Jamal, Helen Burn, Asifa Shaikh
|
EYE - Glaucoma, EYE - Vitreo-Retinal, EYE - General
The authors investigate what proportion of patients undergoing pars plana vitrectomy subsequently developed ocular hypertension or a diagnosis of glaucoma. A systematic review carried out in 2017 including seven studies found that there is evidence that pars plana vitrectomy (PPV)...
Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals
1 February 2018
| Rod McNeil
|
EYE - Glaucoma
Glaucoma is the most frequent cause of irreversible blindness worldwide and the second leading cause of blindness in the UK [1,2]. The global prevalence of glaucoma in 2010 was approximately 3.5% for people aged 40-80 years, according to Jonas et...
Metamorphopsia in idiopathic epiretinal membranes
1 February 2019
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
The Amsler grid is commonly used for self-monitoring, but is qualitative and has low sensitivity. The M-chart reduces the amount of spatial redundancy (‘filling in’) in the Amsler grid. The Orientation Discrimination (OD) test studied in this paper consists of...
Eyecare Glasgow 2025
19 January 2025
-20 January 2025
Eyecare is the biggest conference and exhibition for the optical industry in Scotland and has been running for over 20 years. We will be back at The Hilton Hotel Glasgow, 1 William St, Glasgow G3 8HT on 19th & 20th January 2025 with a packed schedule including the return of the Eyecare Awards.
